Enanta Pharmaceuticals, Inc. (ENTA)
ENTA moved a median of +0.06% 30 minutes after news, and +0.11% by the close. How ENTA actually reacts to news — the realized, point-in-time move the market made, measured across 257 labeled events over the last three years with zero look-ahead.
ENTA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.14% | 35% | 257 |
| 30-min | +0.06% | 50% | 257 |
| 60-min | +0.33% | 57% | 257 |
| to close | +0.11% | 52% | 253 |
| Middle 50% of ENTA reactions | -1.99% to +1.20% |
|---|---|
| Median reaction (30-min) | +0.06% |
| Measured reactions | 257 |
Half of all Enanta Pharmaceuticals, Inc. news events land between -1.99% and +1.20% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ENTA reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 11 | -0.36% | 36% | -3.46% |
| Rating reiterations | 38 | +0.07% | 53% | -0.09% |
| Price-target cuts | 12 | +0.26% | 50% | -0.07% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how ENTA ranks against every other measured name →
That’s how ENTA usually reacts — get an email when it moves on news →Email me when ENTA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ENTA's baseline. Nothing else.
Recent ENTA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026 | Press release | Business Wire | -0.85% | -6.87% | |
| Enanta Pharmaceuticals to Participate in September Investor Conferences | Press release | Business Wire | +0.00% | +1.27% | |
| Form 10-Q ENANTA PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.56% | +0.15% | |
| Form 8-K ENANTA PHARMACEUTICALS For: Jul 02 | SEC filing · Form 8-K | SEC EDGAR | -0.67% | -2.62% | |
| Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus | Press release | Business Wire | -1.89% | +6.35% | |
| Form 8-K ENANTA PHARMACEUTICALS For: Jun 23 | SEC filing · Form 8-K | SEC EDGAR | +1.14% | -2.56% | |
| Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV) | Press release | Business Wire | -0.62% | -1.63% | |
| Form 8-K ENANTA PHARMACEUTICALS For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | -0.62% | -1.63% | |
| Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference | Press release | Business Wire | +0.00% | +0.30% | |
| Form 10-Q ENANTA PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.94% | -2.37% | |
| Form S-8 ENANTA PHARMACEUTICALS | SEC filing · Form S-8 | SEC EDGAR | +0.94% | -2.37% | |
| Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026 | Press release | Business Wire | -3.13% | -3.26% | |
| Form 8-K ENANTA PHARMACEUTICALS For: May 11 | SEC filing · Form 8-K | SEC EDGAR | -3.13% | -3.26% | |
| Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026 | Press release | Business Wire | +3.73% | +2.47% | |
| Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria | Press release | Business Wire | -0.85% | +1.28% | |
| Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026 | Press release | Business Wire | +0.57% | +1.82% | |
| Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI) | Press release | Business Wire | -1.98% | +0.33% | |
| Form 8-K ENANTA PHARMACEUTICALS For: Mar 20 | SEC filing · Form 8-K | SEC EDGAR | +1.38% | +1.63% | |
| Form 8-K ENANTA PHARMACEUTICALS For: Mar 11 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | — | |
| Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference | Press release | Business Wire | -0.69% | +1.66% | |
| Form EFFECT ENANTA PHARMACEUTICALS | SEC filing · Form EFFECT | SEC EDGAR | +0.81% | -0.59% | |
| Form 10-Q ENANTA PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.14% | -1.35% | |
| Form S-3 ENANTA PHARMACEUTICALS | SEC filing · Form S-3 | SEC EDGAR | +0.14% | -1.35% | |
| Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting | Press release | Business Wire | -3.45% | -6.55% | |
| Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025 | Press release | Business Wire | -3.45% | -6.55% | |
| Form 8-K ENANTA PHARMACEUTICALS For: Feb 09 | SEC filing · Form 8-K | SEC EDGAR | -3.45% | -6.55% | |
| Form ARS ENANTA PHARMACEUTICALS For: Sep 30 | SEC filing · Form ARS | SEC EDGAR | -2.63% | +0.46% | |
| Form DEF 14A ENANTA PHARMACEUTICALS For: Mar 11 | SEC filing · Form DEF | SEC EDGAR | -2.63% | +0.46% | |
| Form DEFA14A ENANTA PHARMACEUTICALS | SEC filing · Form DEFA14A | SEC EDGAR | -2.63% | +0.46% | |
| Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook | Press release | Business Wire | +0.29% | -2.33% | |
| Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | Business Wire | +2.46% | -3.54% | |
| Form 10-K ENANTA PHARMACEUTICALS For: Sep 30 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | -1.30% | |
| Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025 | Press release | Business Wire | +0.41% | +1.15% | |
| Form 8-K ENANTA PHARMACEUTICALS For: Nov 17 | SEC filing · Form 8-K | SEC EDGAR | +0.41% | +1.15% | |
| Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences | Press release | Business Wire | +0.56% | +1.79% | |
| Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025 | Press release | Business Wire | +2.25% | -0.04% | |
| Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025 | Press release | Business Wire | +1.28% | -1.95% | |
| Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares | Press release | Business Wire | -0.20% | +0.68% | |
| Form 8-K ENANTA PHARMACEUTICALS For: Sep 30 | SEC filing · Form 8-K | SEC EDGAR | +1.69% | -3.00% | |
| Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock | Press release | Business Wire | -4.06% | +2.61% | |
| Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock | Press release | Business Wire | -4.06% | +2.61% | |
| Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults | Press release | Business Wire | +6.85% | +112.03% | |
| Form 8-K ENANTA PHARMACEUTICALS For: Sep 29 | SEC filing · Form 8-K | SEC EDGAR | +6.85% | +112.03% | |
| Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults | Press release | Business Wire | +6.85% | +112.03% | |
| Enanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial and Administrative Officer Paul J. Mellett Jr. | Press release | Business Wire | +0.17% | -2.65% | |
| Form 8-K ENANTA PHARMACEUTICALS For: Aug 26 | SEC filing · Form 8-K | SEC EDGAR | -0.12% | +1.76% | |
| Enanta Pharmaceuticals to Participate in September Investor Conferences | Press release | Business Wire | +0.91% | -2.83% | |
| Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union | Press release | Business Wire | +0.36% | +6.65% | |
| Form 8-K ENANTA PHARMACEUTICALS For: Aug 20 | SEC filing · Form 8-K | SEC EDGAR | +0.36% | +6.65% | |
| Form 10-Q ENANTA PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.73% | +3.34% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ENTA section they belong to.
Where else ENTA is measured.
ENTA earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Haemonetics Corporation (HAE) | 261 | -0.07% | 44% |
| Avanos Medical, Inc. (AVNS) | 259 | 0.00% | 45% |
| FORTY SEVEN (FTSV) | 257 | +0.01% | 51% |
| SELLAS Life Sciences Group, Inc. (SLS) | 257 | -0.63% | 42% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Enanta Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled ENTA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 257 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of ENTA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ENTA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.